A recent study published in the Journal of Diabetes Research aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus T2DM . This pooled analysis and observational study evaluated data from the vildagliptin post marketing survey PMS the vildagliptin metformin fixed drug combination DC PMS and a retrospective observational study of vildagliptin metformin fixed DC or free DC . The findings revealed that of the 2087 patients recruited 58.94 achieved a glycated haemoglobin HbA1c target of 8804 7.0 at 24 weeks. While the glycemic target achievement rate was markedly higher in patients with baseline HbA1c 8201 8201 7.5 than those with baseline HbA1c 8805 7.5 receiving care at the hospital versus clinic and receiving vildagliptin metformin fixed DC versus free DC. Moreover disease duration baseline HbA1c and DC type had significant effects on drug effectiveness. Thus it was concluded that vildagliptin plus metformin is as an effective treatment option for patients with T2DM in clinical practice settings in Korea.